** Shares of Monopar Therapeutics tumble ~18% to $14.65 post-market after co unveils planned equity raise ** Co announces stock offering on best effort basis; deal size not disclosed
** It plans to use net proceeds for general purposes, including R&D, clinical trial expenditures, among other uses
** Co has 3.9 mln shares outstanding for ~$70 mln market cap and ~2 mln shares of free float, per LSEG
** MNPR closed Monday's session up 5.3% at $17.83 ** On Thurs, stock surged seven-fold from $4.63 to close at $32.66 after co inked licensing deal with AstraZeneca for AZN's experimental drug being tested for Wilson disease, a rare genetic condition that causes the buildup of toxic copper levels
** Rodman & Renshaw exclusive placement agent for stock offering
(Lance Tupper is a Reuters market analyst. The views expressed are his own) ((lance.tupper@thomsonreuters.com lance.tupper@tr.com 1-646-279-6380))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。